Helio Tedesco Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Helio Tedesco Silva has a total of 294 co-authors. Here are the top co-authors by number of shared publications:
- José Osmar Medina-Pestana
Universidade Federal de São Paulo
15 shared publications J. O. Medina-Pestana
Universidade Federal de Sao Paulo, Sao Paulo, Brazil
6 shared publicationsRiberto Garcia
Hospital do Rim e Hipertensao, Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil
6 shared publicationsC.R. Felipe
Universidade Federal de Sao Paulo, Brasil
5 shared publications- Dulce Elena Casarini
Department of Medicine, Discipline Nephrology Universidade Federal de São Paulo (UNIFESP/EPM) São Paulo Brazil
5 shared publications E. Campos
Immunogenetics Institute, Associacao Fundo de Incentivo Pesquisa, Sao Paulo, SP, Brazil
5 shared publications
Latest Publications
- Open Access
- 12 September 2018
- Published by Springer Nature in BMC Nephrology
- Vol. 19 (1) , 1-8
A large, international study on post-transplant glomerular diseases: the TANGO project
Long-term outcomes in kidney transplantation (KT) have not significantly improved during the past twenty years. Despite being a leading cause of graft failure, glomerular disease (GD) recurrence remains poorly understood, due to heterogeneity in disease pathogenesis and clinical presentation, reliance on histopathology to confirm disease recurrence, and the low incidence of individual GD subtypes. Large, international cohorts of patients with GD are urgently needed to better understand the disease pathophysiology, predictors of recurrence, and response to therapy. The Post-TrANsplant GlOmerular Disease (TANGO) study is an observational, multicenter cohort study initiated in January 2017 that aims to: 1) characterize the natural history of GD after KT, 2) create a biorepository of saliva, blood, urine, stools and kidney tissue samples, and 3) establish a network of patients and centers to support novel therapeutic trials. The study includes 15 centers in America and Europe. Enrollment is open to patients with biopsy-proven GD prior to transplantation, including IgA nephropathy, membranous nephropathy, focal and segmental glomerulosclerosis, atypical hemolytic uremic syndrome, dense-deposit disease, C3 glomerulopathy, complement- and IgG-positive membranoproliferative glomerulonephritis or membranoproliferative glomerulonephritis type I-III (old classification). During phase 1, patient data will be collected in an online database. The biorepository (phase 2) will involve collection of samples from patients for identification of predictors of recurrence, biomarkers of disease activity or response to therapy, and novel pathogenic mechanisms. Finally, through phase 3, we will use our multicenter network of patients and centers to launch interventional studies. Most prior studies of post-transplant GD recurrence are single-center and retrospective, or rely upon registry data that frequently misclassify the cause of kidney disease. Systematically determining GD recurrence rates and predictors of clinical outcomes is essential to improving post-transplant outcomes. Furthermore, accurate molecular phenotyping and biomarker development will allow better understanding of individual GD pathogenesis, and potentially identify novel drug targets for GD in both native and transplanted kidneys. The TANGO study has the potential to tackle GD recurrence through a multicenter design and a comprehensive biorepository.
- 12 September 2018
- Published by Springer Nature in BMC Nephrology
- Vol. 19 (1) , 1-8
Open AccessA large, international study on post-transplant glomerular diseases: the TANGO project
Long-term outcomes in kidney transplantation (KT) have not significantly improved during the past twenty years. Despite being a leading cause of graft failure, glomerular disease (GD) recurrence remains poorly understood, due to heterogeneity in disease pathogenesis and clinical presentation, reliance on histopathology to confirm disease recurrence, and the low incidence of individual GD subtypes. Large, international cohorts of patients with GD are urgently needed to better understand the disease pathophysiology, predictors of recurrence, and response to therapy. The Post-TrANsplant GlOmerular Disease (TANGO) study is an observational, multicenter cohort study initiated in January 2017 that aims to: 1) characterize the natural history of GD after KT, 2) create a biorepository of saliva, blood, urine, stools and kidney tissue samples, and 3) establish a network of patients and centers to support novel therapeutic trials. The study includes 15 centers in America and Europe. Enrollment is open to patients with biopsy-proven GD prior to transplantation, including IgA nephropathy, membranous nephropathy, focal and segmental glomerulosclerosis, atypical hemolytic uremic syndrome, dense-deposit disease, C3 glomerulopathy, complement- and IgG-positive membranoproliferative glomerulonephritis or membranoproliferative glomerulonephritis type I-III (old classification). During phase 1, patient data will be collected in an online database. The biorepository (phase 2) will involve collection of samples from patients for identification of predictors of recurrence, biomarkers of disease activity or response to therapy, and novel pathogenic mechanisms. Finally, through phase 3, we will use our multicenter network of patients and centers to launch interventional studies. Most prior studies of post-transplant GD recurrence are single-center and retrospective, or rely upon registry data that frequently misclassify the cause of kidney disease. Systematically determining GD recurrence rates and predictors of clinical outcomes is essential to improving post-transplant outcomes. Furthermore, accurate molecular phenotyping and biomarker development will allow better understanding of individual GD pathogenesis, and potentially identify novel drug targets for GD in both native and transplanted kidneys. The TANGO study has the potential to tackle GD recurrence through a multicenter design and a comprehensive biorepository.
- Open Access
- 1 January 2017
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 39 (2)
Genitourinary tuberculosis - a rare presentation of a still frequent infection in renal transplant recipients
- 1 January 2017
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 39 (2)
Open AccessGenitourinary tuberculosis - a rare presentation of a still frequent infection in renal transplant recipients
- Open Access
- 22 December 2015
- Published by Springer Nature in Transplantation Research
- Vol. 4 (S1) , 5-11
Reviewing 15 years of experience with sirolimus
Here, we review 15 years of clinical use of sirolimus in our transplant center, in context with the developing immunosuppressive strategies use worldwide. The majority of studies were conducted in de novo kidney transplant recipients, using sirolimus (SRL) in combination with calcineurin inhibitors (CNIs). We also explored steroid (ST) or CNI-sparing therapies, including CNI minimization, elimination, or conversion strategies in combination with mycophenolate (MMF/MPS). Pooled long-term outcomes were comparable with those obtained with CNI and antimetabolite combination. Surprisingly, there are still several areas that need further investigation to improve the risk/benefit profile of SRL in kidney transplantation, including pharmacokinetic/pharmacodynamic drug-to-drug interaction with cyclosporine (CsA) or tacrolimus (TAC), mechanisms of SRL-associated adverse reactions and combinations with other drugs such as belatacept and once-daily TAC, possibly leading to improved long-term adherence. These studies, along with others investigating the benefits of SRL associated lower viral infections and malignancies, are essential as we do not expect the introduction of new immunosuppressive drugs in the near future.
- 22 December 2015
- Published by Springer Nature in Transplantation Research
- Vol. 4 (S1) , 5-11
Open AccessReviewing 15 years of experience with sirolimus
Here, we review 15 years of clinical use of sirolimus in our transplant center, in context with the developing immunosuppressive strategies use worldwide. The majority of studies were conducted in de novo kidney transplant recipients, using sirolimus (SRL) in combination with calcineurin inhibitors (CNIs). We also explored steroid (ST) or CNI-sparing therapies, including CNI minimization, elimination, or conversion strategies in combination with mycophenolate (MMF/MPS). Pooled long-term outcomes were comparable with those obtained with CNI and antimetabolite combination. Surprisingly, there are still several areas that need further investigation to improve the risk/benefit profile of SRL in kidney transplantation, including pharmacokinetic/pharmacodynamic drug-to-drug interaction with cyclosporine (CsA) or tacrolimus (TAC), mechanisms of SRL-associated adverse reactions and combinations with other drugs such as belatacept and once-daily TAC, possibly leading to improved long-term adherence. These studies, along with others investigating the benefits of SRL associated lower viral infections and malignancies, are essential as we do not expect the introduction of new immunosuppressive drugs in the near future.
- 1 December 2014
- Published by Elsevier in Transplantation Proceedings
- Vol. 46 (10) , 3416-3419
Outcomes in Obese Kidney Transplant Recipients
- 1 December 2014
- Published by Elsevier in Transplantation Proceedings
- Vol. 46 (10) , 3416-3419
Outcomes in Obese Kidney Transplant Recipients
- 1 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 540-541
Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Impact On Glycemic Parameters.
- 1 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 540-541
Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Impact On Glycemic Parameters.
- 1 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 22
Association of Genetic Polymorphisms With Delayed Kidney Graft Function.
- 1 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 22
Association of Genetic Polymorphisms With Delayed Kidney Graft Function.
- 1 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 624-625
Kidney Transplantation in HIV-Infected Recipients. A Report From the Brazilian Experience.
- 1 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 624-625
Kidney Transplantation in HIV-Infected Recipients. A Report From the Brazilian Experience.
- 1 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 538
Open-Label Study of Planned Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft.
- 1 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 538
Open-Label Study of Planned Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft.
- 24 February 2014
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 21 (Suppl 1) , A83
DI-033 Safety profile study of planned randomised conversion from tacrolimus to sirolimus-based immunosuppressive regimen inde novokidney transplant recipients
Background For years, we have been looking for effective immunosuppressive regimens, but tolerability of the drug is important too. Otherwise patients cannot tolerate the drug and the incidence of death, graft loss or premature treatment withdrawal will increase. New therapeutic approaches have been developed such as calcineurin inhibitors for mTOR inhibition. Our study aimed to increase the understanding of immunosuppression and adverse effects. Purpose The purpose of this retrospective analysis was to investigate the short- and long-term safety profile of immunosuppressive regimes evaluated in the original study. In this current analysis, data from only a single centre were used, consisting of data from 185 kidney transplant recipients previously enrolled in the core study, between February/2008 to May/2010. These patients were followed for two years post-transplant. Materials and methods This study is a retrospective safety analysis data from a larger open-label, randomised, multicentre study titled “Planned randomised conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients”, previously approved by our local ethics committee. Of 169 patients evaluated at month 3, 160 met the criteria for intervention. Of these 60 patients converted to sirolimus and 60 kept on initial tacrolimus-based maintenance therapy, as earlier randomised. The 41 patients who did not meet the month 3 criteria for the core protocol interventional plan were considered a non-criteria group and were also followed for 12 months. Results Biochemical and haematological parameters were recorded at fixed time visits (month 3, month 12 and month 24) from groups (SRL versus TAC), including haemoglobin g/dL (M3:12.8 ± 1.61 × 13.1 ± 2.02; M12:13.6 ± 2.47; X14.1 ± 1.64; M24:13.41.83 ± X14 ± 1.69), leukocytesN/mm3 (M3:6938 ± 3218 × 64912789 ±; M12:6811 ± 2434X6011 ± 1985; M24:7622 ± 2902X7598 ± 2378), urine protein to creatinine ratio (M3: 0.3 ± 0.8X 0.1 ± 0.21; M120.3 ± 0.6X0.2X0.6; M24:0.5 ± 0.3 ± 8), creatinine mg/dL (M3: 1.30 ± 0.33X1.25 ± 0.30; M12:1.29 ± 0.33X1.27 ± 0.35; M24:1.33 ± 0.41X1.25 ± 0.35), clearance mL/min/m2 (M3; M12; M24) cholesterol mg/dL (M3:17542 ± X179 ± 35; M12:225 ± 47X190 ± 43; M24:221 ± 53X187 ± 54) and cholesterol fractions, including LDL mg/dL, (M3:97 ± 35 × 102 ± 30; M12:134 ± 38 × 112 ± 34; M24:131 ± 39 × 108 ± 34) were collected. Conclusions At the moment, the current study showed that biochemical and haematological values did not differ statistically, however, cholesterol fractions showed differences between immunosuppression regimes. In addition, all adverse events (serious or not) reported at medical records were evaluated, according to the Common Terminology Criteria for Adverse Event v.4. The incidence of infections and gastrointestinal disorders pre- and post-conversion was collected. This information will be explored at greater depth. No conflict of interest.
- 24 February 2014
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 21 (Suppl 1) , A83
DI-033 Safety profile study of planned randomised conversion from tacrolimus to sirolimus-based immunosuppressive regimen inde novokidney transplant recipients
Background For years, we have been looking for effective immunosuppressive regimens, but tolerability of the drug is important too. Otherwise patients cannot tolerate the drug and the incidence of death, graft loss or premature treatment withdrawal will increase. New therapeutic approaches have been developed such as calcineurin inhibitors for mTOR inhibition. Our study aimed to increase the understanding of immunosuppression and adverse effects. Purpose The purpose of this retrospective analysis was to investigate the short- and long-term safety profile of immunosuppressive regimes evaluated in the original study. In this current analysis, data from only a single centre were used, consisting of data from 185 kidney transplant recipients previously enrolled in the core study, between February/2008 to May/2010. These patients were followed for two years post-transplant. Materials and methods This study is a retrospective safety analysis data from a larger open-label, randomised, multicentre study titled “Planned randomised conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients”, previously approved by our local ethics committee. Of 169 patients evaluated at month 3, 160 met the criteria for intervention. Of these 60 patients converted to sirolimus and 60 kept on initial tacrolimus-based maintenance therapy, as earlier randomised. The 41 patients who did not meet the month 3 criteria for the core protocol interventional plan were considered a non-criteria group and were also followed for 12 months. Results Biochemical and haematological parameters were recorded at fixed time visits (month 3, month 12 and month 24) from groups (SRL versus TAC), including haemoglobin g/dL (M3:12.8 ± 1.61 × 13.1 ± 2.02; M12:13.6 ± 2.47; X14.1 ± 1.64; M24:13.41.83 ± X14 ± 1.69), leukocytesN/mm3 (M3:6938 ± 3218 × 64912789 ±; M12:6811 ± 2434X6011 ± 1985; M24:7622 ± 2902X7598 ± 2378), urine protein to creatinine ratio (M3: 0.3 ± 0.8X 0.1 ± 0.21; M120.3 ± 0.6X0.2X0.6; M24:0.5 ± 0.3 ± 8), creatinine mg/dL (M3: 1.30 ± 0.33X1.25 ± 0.30; M12:1.29 ± 0.33X1.27 ± 0.35; M24:1.33 ± 0.41X1.25 ± 0.35), clearance mL/min/m2 (M3; M12; M24) cholesterol mg/dL (M3:17542 ± X179 ± 35; M12:225 ± 47X190 ± 43; M24:221 ± 53X187 ± 54) and cholesterol fractions, including LDL mg/dL, (M3:97 ± 35 × 102 ± 30; M12:134 ± 38 × 112 ± 34; M24:131 ± 39 × 108 ± 34) were collected. Conclusions At the moment, the current study showed that biochemical and haematological values did not differ statistically, however, cholesterol fractions showed differences between immunosuppression regimes. In addition, all adverse events (serious or not) reported at medical records were evaluated, according to the Common Terminology Criteria for Adverse Event v.4. The incidence of infections and gastrointestinal disorders pre- and post-conversion was collected. This information will be explored at greater depth. No conflict of interest.